CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
953.09MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.0200xvs all stocks
52-Week Change
148.07%vs all stocks
Market Capitalization
953.09MUSDvs all stocks (USD)
Enterprise Value
620.63MUSDvs all stocks (USD)
Forward P/E
-5.55xvs Biotechnology peers
Price to Book (MRQ)
2.96xvs Biotechnology peers
Enterprise to EBITDA
-2.80xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-31.36%vs Biotechnology peers
Return on Equity (TTM)
-50.30%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-221.49MUSDvs all stocks (USD)
Net Income (TTM)
-208.34MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-159.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.23MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-241.65MUSDvs all stocks (USD)
Pre-tax Income
-219.88MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-219.88MUSDFY2025 · Dec 31, 2025EBIT
-241.65MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-241.34MUSDFY2025 · Dec 31, 2025Research & Development
187.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
54.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.21MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-219.88MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-184.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
-184.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
88.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-219.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
311.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.04MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-839.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-49.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-236.53MUSDFY2025 · Dec 31, 2025Sale of Investments
416.57MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
179.99MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
64.35MSharesUpdated Sep 27, 2026Float Shares
48.09MSharesUpdated Sep 27, 2026Shares Short
9.63MSharesUpdated Sep 27, 2026Short Ratio
12.27daysvs all stocks
Short % of Shares Outstanding
20.84%vs all stocks
% Held by Insiders
0.43%vs all stocks
% Held by Institutions
112.62%vs all stocks
Total Cash (MRQ)
334.54MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.20USDUpdated Sep 27, 2026Total Debt (MRQ)
2.07MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0064xvs Biotechnology peers
Current Ratio (MRQ)
8.42xvs Biotechnology peers
Book Value per Share (MRQ)
5.00USDUpdated Sep 27, 2026Total Assets
448.37MUSDvs all stocks (USD)
Total Current Assets
386.76MUSDFY2025 · Dec 31, 2025Total Liabilities
39.64MUSDFY2025 · Dec 31, 2025Total Non-current Assets
61.62MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.90MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
289.56MUSDFY2025 · Dec 31, 2025Accounts Payable
841.00KUSDFY2025 · Dec 31, 2025Short-term Debt
780.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
996.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.90MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-588.12MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
408.73MUSDvs all stocks (USD)
52-Week Low
5.68USDUpdated Sep 27, 202652-Week High
23.19USDUpdated Sep 27, 202652-Week Change
148.07%vs all stocks
Beta
0.0200xvs all stocks
50-Day MA
19.71USDUpdated Sep 27, 2026200-Day MA
15.26USDUpdated Sep 27, 2026Avg 10-Day Volume
1.59MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.02MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-3.11USDUpdated Sep 27, 2026Other Income / Expense
-443.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Altman Z-Score 11.74: safe zoneNotable
Altman Z-Score: 11.74
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow